

Cholesterol and Alzheimer's disease

Is there a link?

Mikael Simons, MD; Patrick Keller, PhD; Johannes Dichgans, MD; and Jörg B. Schulz, MD

Article abstract—The A β -amyloid peptide (A β), the main component of amyloid plaques, is derived by proteolytic cleavage from the amyloid precursor protein (APP). Epidemiologic and biochemical data suggest a link between cholesterol, APP processing, A β , and Alzheimer's disease. Two recent epidemiologic studies indicate that there is a decreased prevalence of AD associated with the use of cholesterol-lowering drugs that inhibit 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase inhibitors or statins). Experiments in cell culture and in vivo demonstrate that treatment with statins reduces production of A β . The authors discuss how cholesterol might modulate A β deposit formation. As neurons receive only small amounts of exogenous cholesterol, statins that efficiently cross the blood-brain barrier may reduce the amount of neuronal cholesterol below a critical level. Decreased neuronal cholesterol levels inhibit the A β -forming amyloidogenic pathway possibly by removing APP from cholesterol- and sphingolipid-enriched membrane microdomains. In addition, depletion of cellular cholesterol levels reduces the ability of A β to act as a seed for further fibril formation. These intriguing relationships raise the hopes that cholesterol-lowering strategies may influence the progression of AD.

NEUROLOGY 2001;57:1089–1093

The amyloid hypothesis. The A β -amyloid peptide (A β) is the main component of senile plaques, which are the pathologic hallmark of AD. This finding has led to the amyloid hypothesis, which states that A β triggers a cascade eventually leading to neurodegeneration.^{1,2} A β occurs in two different forms, A β 40 and A β 42, varying in the length at the C terminus. It is the longer A β 42 that aggregates more avidly and is thought to be the most important trigger of the amyloid cascade. Considerable experimental support for this hypothesis comes from genetic data of the small fraction of autosomal dominant inherited forms of AD, as disease-linked mutations in the genes of amyloid precursor protein (APP), presenilin 1, and presenilin 2 all result in increased production of A β 42.³ The cellular events that lead to A β production are well known. A β is part of APP, a transmembrane protein containing a large N-terminal ectodomain and a small C-terminal cytoplasmic tail. During intracellular transport, APP undergoes a series of proteolytic cleavages that lead to the release of either amyloidogenic A β or α APPsec, the secreted ectodomain of APP.⁴ Most APP is cleaved by α -secretase within the A β domain to release α APPsec. A β is produced in two sequential steps from APP, which has escaped processing at the α site. There, the first cleavage occurs in the luminal

domain by β -secretase, a newly identified aspartyl protease (BACE 1) that leaves behind a membrane-bound C-terminal fragment of 10 kD.⁵ This β stub is the substrate of γ -secretase, which appears to be a multiprotein complex containing at least presenilin 1, presenilin 2, and nicastrin.⁶ Processing within the β stub occurs at different sites to generate A β species of either 40, 42, or 43 amino acids in length. Physiologically, these secreted amyloid peptides are cleared from the extracellular space. However, in the case of AD when A β 42 production is increased, clearance is not complete and amyloid fibrils start to form. These A β 42 deposits are thought to serve as seeds that trigger the formation of senile plaques,⁷ which is balanced by factors that influence the clearance/deposition of A β . The apolipoprotein apoE is believed to be such a factor.

Cholesterol metabolism in the brain. In intestinal epithelial cells, dietary cholesterol is incorporated into chylomicrons. They are transported to the liver, where they are taken up as chylomicron remnants by receptor-mediated endocytosis. The liver releases this cholesterol in the form of very-low-density lipoproteins that contain three apolipoproteins (E, C, and B100), which subsequently are transformed to low-density lipoproteins (LDL) with mainly apolipoprotein B100 as their coat protein. Those LDL par-

From the Department of Neurology, University of Tübingen (Drs. Simons, Dichgans, and Schulz), and Max Planck Institute of Molecular Cell Biology and Genetics, Dresden (Dr. Keller), Germany.

Received April 13, 2001. Accepted in final form June 5, 2001.

Address correspondence and reprint requests to Dr. M. Simons, Department of Neurology, Hoppe-Seyler-Strasse 3, 72076 Tübingen, Germany; e-mail: mika_simons@hotmail.com

ticles are the major source of cholesterol for most cells of the body. However, cells are also able to produce cholesterol by de novo synthesis in the endoplasmic reticulum. Excess cholesterol is stored as esterified cholesterol in lipid droplets within the cell or removed by high-density lipoproteins (HDL). By these four mechanisms (LDL uptake, de novo synthesis, cholesterol esterification, and HDL efflux), cells manage to keep cholesterol levels in their membranes fairly constant. This process is tightly regulated and involves transcription factors called sterol regulatory element-binding proteins (SREBP). The activity of SREBP is controlled by the SREBP cleavage-activating protein (SCAP) that contains sterol-sensing domains. When cholesterol levels are low, SREBP are activated by SCAP and in turn activate genes that control LDL internalization, de novo synthesis, and cholesterol esterification.⁸

Although cholesterol homeostasis has been studied in detail in peripheral cells, relatively little is known about cholesterol metabolism in the brain, the organ richest in cholesterol.⁹ As the brain is located behind the blood–brain barrier, it does not compete for circulating plasma lipoproteins. Indeed, the CSF has a distinct spectrum of lipoproteins as compared with that of plasma.^{10,11} Human CSF lipoproteins exist as two major classes, the apolipoproteins apoE and apoAI, which form particles that resemble HDL.¹² Apolipoprotein B100, which is involved in transport of exogenous cholesterol to cells by LDL particles, is very low in the CSF. Influx and efflux of cholesterol in brain cells must therefore follow different rules. Early work indeed suggested that cholesterol is synthesized locally in the brain and only a little is taken up from the plasma (figure 1).¹³ For oligodendrocytes, cells that, owing to their production of the myelin membrane, contain a tremendous amount of cholesterol, there is also evidence that cholesterol is derived from de novo synthesis.¹⁴ Removal of brain cholesterol may not occur via lipoproteins but by conversion to 24-hydroxycholesterol, a compound that passes the blood–brain barrier.¹⁵ Apolipoproteins present in the brain thus do not seem to play a major role in lipid transfer from and to the brain but most likely exert their function by redistributing cholesterol within the brain.¹⁶ After nerve injury, apoE production, for example, is induced in astrocytes from where it is delivered to sprouting axons and remyelination glial cells as apoE–lipid complexes. In the brain, apoE could be involved in transfer of cholesterol from regions high in cholesterol to regions low in cholesterol.¹⁶

The fact that cellular cholesterol levels are so tightly regulated raises the question of the function of cholesterol in membranes. It has been long known that cholesterol regulates important physical properties of the cell membrane. Cholesterol enhances the rigidity of the membrane and makes it therefore less permeable for small water-soluble molecules. Recent




Figure 1. Neurons receive cholesterol almost entirely from in situ synthesis. Only small amounts of neuronal cholesterol come from uptake from the plasma. Neurons obtain cholesterol either by de novo synthesis or by transfer of cholesterol from other cells of the CNS. Statins reduce de novo synthesis of cholesterol by inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase). This might reduce cholesterol to a critical level in neuronal cells such that A β -amyloid peptide production would be affected.

advances showing that cholesterol plays an important role in membrane compartmentalization now extend the function of cholesterol.¹⁷ It also is an essential component of lipid rafts, lateral assemblies of cholesterol and sphingolipids in the exoplasmic leaflet of the bilayer.¹⁷ The formation of these microdomains is thought to occur by self-association of sphingolipids via their long saturated hydrocarbon chains. Cholesterol condenses this packing by positioning between these hydrocarbon chains below the large head groups of the sphingolipids. These interactions lead to the formation of a less fluid, liquid-ordered phase, separate from a phosphatidylcholine-rich liquid-disordered phase. Lipid rafts are small, about 50 nm in size, and float in the exoplasmic part of the fluid membrane.¹⁸ Only when the amounts of cholesterol and sphingolipids continuously increase, as in the case of myelin in oligodendrocytes, may lipid rafts become the dominating lipid phase.¹⁹ Rafts function by separating and condensing molecules, such that they can exert their function in concert. Signal transduction and generation of membrane polarity are examples of processes that involve the interplay of molecules within lipid rafts.¹⁷ Cholesterol not only is an essential component of lipid rafts but also serves an important role in keeping them in a functional state.

Cholesterol and AD. There are epidemiologic data that point to a relationship between cholesterol and AD. Cross-sectional analyses have described an

association of atherosclerosis for which hypercholesterolemia is an important risk factor and AD.²⁰ Longitudinal studies have suggested a relationship between elevated midlife cholesterol levels and late-life cognitive impairment or AD.^{21,22}

Two recent retrospective clinical studies indicate that there is a decreased prevalence of AD associated with the use of statins to treat hypercholesterolemia. Those drugs cross the blood-brain barrier efficiently and reduce de novo cholesterol synthesis by inhibition of the ubiquitously expressed enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase) (see figure 1). One study²³ compared the prevalence of probable AD in groups of patients receiving HMG-CoA reductase inhibitors with that in patients receiving medication to treat hypertension or cardiovascular disease. The investigators found that the likelihood to develop AD was 60 to 73% lower in the cohort taking statins.²³ Another study²⁴ showed in a case-control analysis that the risk of dementia is up to 70% lower in patients using statins compared with patients with untreated hyperlipidemia or patients receiving other lipid-lowering drugs (fibrates, cholestyramine, or nicotinic acid).

In addition, animal studies have revealed an association of amyloid production and cholesterol. Whereas rabbits and rats fed with a cholesterol-rich diet have a tendency to accumulate A β in the brain,^{25,26} guinea pigs treated with statins have lower levels of A β in the CSF.²⁷ How can these effects be explained?

Previous studies have shown that cholesterol modulates the processing of APP in cultures of rat hippocampal neurons.²⁸ A β production and secretion were dramatically reduced when cellular cholesterol levels were reduced by inhibiting de novo synthesis with statins alone or in combination with the cholesterol-extracting agent methyl- β -cyclodextrin.²⁷⁻³⁰ Cholesterol depletion also led to a marked reduction of the C-terminal β stub, suggesting that β -secretase cleavage depended on cholesterol.²⁸ In contrast, secretion of the APP ectodomain generated by the nonamyloidogenic α -secretase pathway was shown to increase.³⁰ Thus, cholesterol depletion seems to inhibit the amyloidogenic (β - and γ -secretase) pathway while stimulating the nonamyloidogenic (α -secretase) pathway. What is the reason for the cholesterol dependence of β cleavage? In neurons, a small but substantial fraction of APP (approximately 5%) is turned into amyloidogenic A β , whereas the majority is cleaved by α -secretase to release α APPsec.³¹ Several studies have shown that a small fraction of APP in neurons is associated with lipid rafts.^{28,32,33} This finding was based on the presence of APP in detergent-resistant membranes. Interestingly, cholesterol depletion not only reduced A β secretion but also decreased to a similar extent the association of APP with detergent-resistant membranes.²⁸ This and the observation that A β directly associates with a lipid raft fraction derived




Figure 2. A model of the compartmentalization of amyloidogenic (β cleavage) and nonamyloidogenic (α cleavage) of amyloid precursor protein (APP). Nonamyloidogenic processing of APP involves cleavage by α -secretase within the A β -amyloid peptide (A β) domain to release α APPsec. Low cholesterol stimulates the nonamyloidogenic pathway. α -Secretase might therefore require a membrane domain, which is poor in cholesterol. Generation of A β (amyloidogenic processing) occurs in two sequential steps: cleavage by β -secretase and γ -secretase. β -Secretase cleavage, in contrast, requires cholesterol and might therefore occur in cholesterol-rich membrane domains. The content of cholesterol in the membrane is shown in black in the figure.

from brain tissue led us to hypothesize that the amyloidogenic processing of APP occurs within rafts, whereas nonamyloidogenic α cleavage takes place outside rafts (figure 2).^{28,32} This compartmentalization would also explain the mutual exclusion of α and β cleavage.

Interestingly, A β within rafts seems to promote fibrillogenesis of soluble A β . A recent study³⁴ suggested that A β associated with cholesterol-rich membranes adopts a different conformation, acting as a "seed" for amyloid formation. Depletion of cellular cholesterol reduced the seeding properties of A β . How rafts change the conformation of A β is not known. However, the ganglioside GM1, a raft lipid, is known to bind to A β and thereby might change its secondary structure.³⁵⁻³⁷

Caveolae, which are considered to be a specific form of raft, are involved in cholesterol-dependent regulation of specific signal transduction pathways. Interestingly, statins reduce inflammatory response by inhibiting the induction of inducible nitric oxide synthase, an enzyme that localizes to caveolae.^{38,39} Reducing brain inflammatory responses may be important in AD where immune cells are activated.

Furthermore, cholesterol may also exert indirect effects via the allele $\epsilon 4$ of *APOE*, a susceptibility gene of AD.⁴⁰ Several hypotheses for the role of apoE have been put forward: for example, increased A β fibrillogenesis, decreased A β clearance, and decreased neuronal repair for *APOE4* compared with *APOE2* and *APOE3*.⁴¹ However, it is also possible that apoE contributes to the pathology of AD by effects on lipid metabolism.⁴² Indeed, the *APOE4* allele is associated with higher cholesterol levels.⁴³ Furthermore, a recent study has shown that apoE4 promotes the efflux of cholesterol from neurons less efficiently than apoE2 and apoE3.⁴⁴ We propose, therefore, that apoE could also be involved in regulating the cholesterol supply to neurons that generate A β . The increased risk to develop AD in patients carrying the *APOE4* allele could thus be explained by the associated higher cholesterol levels that would allow more A β to be produced.

The different possibilities of how lowering cholesterol levels might influence AD can now be challenged experimentally. For patients with AD, double-blind prospective placebo-controlled clinical trials with statins will be of importance. These are on their way and will, it is hoped, be beneficial for patients with AD.

References

1. Selkoe DJ. Alzheimer's disease: a central role for amyloid. *J Neuropathol Exp Neurol* 1994;53:438–447.
2. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. *Science* 1992;256:184–185.
3. Younkin SG. Evidence that A β 42 is the real culprit in Alzheimer's disease. *Ann Neurol* 1995;37:287–288.
4. Haass C, Selkoe DJ. Cellular processing of β -amyloid precursor protein and the genesis of amyloid β -peptide. *Cell* 1993;75:1039–1042.
5. Howlett DR, Simmons DL, Dingwall C, Christie G. In search of an enzyme: the beta-secretase is an aspartic proteinase. *Trends Neurosci* 2000;23:565–570.
6. Yu G, Nishimura M, Arawaka S, et al. Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and beta-APP processing. *Nature* 2000;407:48–54.
7. Jarrett JT, Lansbury PT Jr. Seeding. "One-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? *Cell* 1993;73:1055–1058.
8. Brown MS, Goldstein JL. The SREBP pathway. Regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. *Cell* 1997;89:331–340.
9. Dietschy JM, Turley SD. Cholesterol metabolism in the brain. *Curr Opin Lipidol* 2001;12:105–112.
10. Roheim PS, Carey M, Forte T, Vega GL. Apolipoproteins in human cerebrospinal fluid. *Proc Natl Acad Sci USA* 1979;76:4646–4649.
11. Ladu MJ, Reardon C, Van Eldik L, et al. Lipoproteins in the central nervous system. *Ann NY Acad Sci* 2000;903:167–175.
12. Pitas RE, Boyles JK, Lee SH, Hui D, Weisgraber KH. Lipoproteins and their receptors in the central nervous system. *J Biol Chem* 1987;262:14352–14360.
13. Kabara JJ. A critical review of brain cholesterol metabolism. *Prog Brain Res* 1973;40:363–382.
14. Morell P, Jurevics H. Origin of cholesterol in myelin. *Neurochem Res* 1996;21:463–470.
15. Björkholm I, Lütjohann D, Diczfalussy U, et al. Cholesterol homeostasis in human brain: turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation. *J Lipid Res* 1998;39:1594–1600.
16. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. *Science* 1988;240:622–631.
17. Simons K, Ikonen E. Functional rafts in cell membranes. *Nature* 1997;387:569–572.
18. Pralle A, Keller P, Florin EL, Simons K, Hörber JK. Sphingolipid-cholesterol rafts diffuse as small entities in the plasma membrane of mammalian cells. *J Cell Biol* 2000;148:997–1008.
19. Simons M, Krämer E-M, Thiele C, Stoffel W, Trotter J. Assembly of myelin by association of proteolipid protein with cholesterol and galactosylceramide-rich membrane domains. *J Cell Biol* 2000;151:143–153.
20. Hofman A, Ott A, Breteler MMB, et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam study. *Lancet* 1997;349:151–154.
21. Notkola I-L, Sulkava R, Pekkanen J, et al. Serum cholesterol, apolipoprotein E4, and Alzheimer's disease. *Neuroepidemiology* 1998;17:14–20.
22. Kivipelto M, Helkala E-L, Hänninen T, et al. Midlife vascular risk factors and late-life mild cognitive impairment. A population-based study. *Neurology* 2001;56:1683–1689.
23. Wolozin B, Kellman W, Rousseau P, Celesia CC, Siegel G. Decreased prevalence of Alzheimer's disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. *Arch Neurol* 2000;57:1439–1443.
24. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. *Lancet* 2000;356:1627–1631.
25. Sparks DL. Interneuron-amyloid immunoreactivity in the CNS. *Neurobiol Aging* 1996;17:291–299.
26. Refolo LM, Pappolla MA, Malester B, et al. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. *Neurobiol Dis* 2000;7:321–331.
27. Fassbender K, Simons M, Bergmann C, et al. Simvastatin strongly reduces Alzheimer's disease A β 42 and A β 40 levels in vitro and in vivo. *Proc Natl Acad Sci USA* 2001;98:5856–5861.
28. Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K. Cholesterol depletion inhibits the generation of β -amyloid in hippocampal neurons. *Proc Natl Acad Sci USA* 1998;95:6460–6464.
29. Frears E, Stephens D, Walters C, Davies H, Austen B. The role of cholesterol in the biosynthesis of beta-amyloid. *Neuroreport* 1999;10:1699–1705.
30. Kojro E, Gimpl G, Lammich S, März W, Fahrenholz F. Low cholesterol stimulates the nonamyloidogenic pathway by its effects on the α -secretase ADAM 10. *Proc Natl Acad Sci USA* 2001;98:5815–5820.
31. Simons M, De Strooper B, Multhaup G, Tienari PJ, Dotti CG, Beyreuther K. Amyloidogenic processing of the human amyloid precursor protein in primary cultures of rat hippocampal neurons. *J Neurosci* 1996;16:899–908.
32. Lee SJ, Liyanage U, Bickel PE, Xia W, Lansbury PT, Kosik K. A detergent-insoluble membrane compartment contains A β in vivo. *Nat Med* 1998;4:730–734.
33. Bouillot C, Prochianz A, Rougon G, Alliquant B. Axonal amyloid precursor protein expressed by neurons in vitro is present in a membrane fraction with caveolae-like properties. *J Biol Chem* 1996;271:7640–7644.
34. Mizuno T, Nakata M, Naiki H, et al. Cholesterol-dependent generation of a seeding amyloid β -protein in cell culture. *J Biol Chem* 1999;274:15110–15114.
35. Yanagisawa K, Odaka A, Suzuki N, Ihara Y. GM1 ganglioside-bound amyloid beta-protein (A β): a possible form of preamyloid in Alzheimer's disease. *Nat Med* 1995;1:1062–1066.
36. McLaurin J, Chakrabarty A. Membrane disruption by Alzheimer beta-amyloid peptides mediated through specific binding to either phospholipids or gangliosides. Implications for neurotoxicity. *J Biol Chem* 1996;271:26482–26489.
37. Choo-Smith LP, Garzon-Rodriguez W, Glabe CG, Surewicz WK. Acceleration of amyloid fibril formation by specific binding of A β (1–40) peptide to ganglioside-containing membrane vesicles. *J Biol Chem* 1997;272:22987–22990.
38. Pahan K, Sheikh FG, Namboodiri AM, Singh I. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. *J Clin Invest* 1997;100:2671–2679.
39. Garcia-Cardena G, Martasek P, Masters BS, et al. Dissecting the interaction between nitric oxide synthase (NOS) and caveolin. Functional significance of the NOS caveolin binding domain in vivo. *J Biol Chem* 1997;272:25437–25440.

40. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. *Proc Natl Acad Sci USA* 1993;90:1977–1981.
41. Weisgraber KH, Mahley RW. Human apolipoprotein E: the Alzheimer's disease connection. *FASEB J* 1996;10:1485–1494.
42. Jarvik GP, Wijsman EM, Kukull WA, Schellenberg GD, Yu C, Larson EB. Interaction of apolipoprotein E genotype, total

cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study. *Neurology* 1995;45:1092–1096.

43. Sing CF, Davignon J. Role of the apolipoprotein E polymorphism in the determining normal plasma lipid and lipoprotein variation. *Am J Hum Genet* 1985;37:268–285.
44. Michikawa M, Fan QW, Isobe I, Yanagisawa K. Apolipoprotein E exhibits isoform-specific promotion of lipid efflux from astrocytes and neurons in culture. *J Neurochem* 2000;74:1008–1016.

NeuroImages




Figure. Posterior view of left cerebellopontine angle showing loop (L) of the anterior inferior cerebellar artery separated from groove (G) in the trigeminal nerve by a Teflon sponge (Boston Scientific, Medox Medical Industries, Oakland, NJ) (S). Note the seventh and eighth nerve complex (7) (superior and inferior vestibular nerves hiding facial and acoustic nerves) and sixth nerve (6).

Microvascular decompression for trigeminal neuralgia

Rafael Allende, MD, Sandeep Teja, MD,
Cargill H. Alleyne, Jr., MD, Rochester, NY

A 58-year-old woman presented with sharp, lancinating pain in the V2 distribution unresponsive to carbamazepine. Her neurologic examination and an MRI were unremarkable. The patient underwent a posterior fossa craniectomy for microvascular decompression (MVD) where a loop of the anterior inferior cerebellar artery was

noted to compress the trigeminal nerve. Her symptoms resolved postoperatively. Trigeminal neuralgia most commonly affects the V2 and V3 branches. Microvascular decompression has an initial success rate of 85 to 95% with a recurrence rate of 20% and 30%, at 6 and 10 years.^{1,2} There is no sensory loss associated with MVD.

1. Jannetta PJ. Trigeminal neuralgia: treatment by microvascular decompression. In: Wilkins RH, Rengachary SS, eds. *Neurosurgery*, vol III. New York: McGraw-Hill, 1996:3961–3968.
2. Barker FG, Jannetta PJ, Bissonette DJ, Larkins MV, Jho HD. The long-term outcome of microvascular decompression for trigeminal neuralgia. *N Engl J Med* 1996;334:1077–1083.